BOXER CAPITAL LLC
Q2 2023 Form 13-F

SAN DIEGO, CALIFORNIA
CIK 0001465837 · CRD 330106 · SEC-registered investment adviser
$2.2B Reported Value Total

BOXER CAPITAL MANAGEMENT, LLC reports 1 total accounts under management (AUM). There are 1 discretionary accounts valued at $2,543,913,691, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
2 funds · $578.2M gross asset value
Hedge Fund: $578.2M
Source: Form ADV filed 2026-05-11
Reported value
$2.2B
Quarter over quarter
+6.8%
Holdings
79
Top-10 concentration
46.0%

Filing Structure

Reports holdings for

  • Aviva Holdings Ltd. (not a 13F filer in our records) · File #28-17342 · Q1 2016 – Q3 2017 · declared by one filing
  • Aviva Holdings Ltd. (not a 13F filer in our records) · Q4 2015 – Q4 2015 · declared by one filing

Key People

Form ADV owners & control persons
LLC Boxer Holdings Gp
MANAGER
Aaron Isaac Davis
MANAGER AND MEMBER
Tiffany Ann Ayres
CHIEF COMPLIANCE OFFICER AND LEGAL COUNSEL

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2023 13F record

Q2 2023 13F filing summary

Q2 2023 Form 13F portfolio summary
Period of report June 30, 2023
Filed August 14, 2023
Form 13F-HR
Reported value $2.2B
Positions 79
Change in reported value +5.9%
New positions 9
Exited positions 5
Position turnover 16.7%
Top-10 concentration 46.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q4 2024 13F
Filed Feb 14, 2025
0 $0
Q3 2024 13F
Filed Nov 14, 2024
68 $2.0B
Q2 2024 13F
Filed Aug 14, 2024
61 $1.9B
Q1 2024 13F
Filed May 15, 2024
59 $2.0B
Q4 2023 13F
Filed Feb 14, 2024
52 $2.0B
Q3 2023 13F
Filed Nov 14, 2023
73 $1.9B
Q2 2023 13F
Filed Aug 14, 2023
79 $2.2B
Q1 2023 13F
Filed May 15, 2023
75 $2.0B
Q4 2022 13F
Filed Feb 14, 2023
71 $1.9B
Q3 2022 13F
Filed Nov 14, 2022
73 $1.8B
Q2 2022 13F
Filed Aug 15, 2022
76 $1.6B
Q1 2022 13F
Filed May 16, 2022
74 $1.9B
Q4 2021 13F
Filed Feb 14, 2022
70 $2.6B
Q3 2021 13F
Filed Nov 15, 2021
87 $2.9B
Q2 2021 13F
Filed Aug 16, 2021
95 $2.8B
Q1 2021 13F
Filed May 17, 2021
85 $2.9B
Q4 2020 13F
Filed Feb 16, 2021
78 $3.1B
Q3 2020 13F
Filed Nov 16, 2020
75 $2.9B
Q2 2020 13F
Filed Aug 14, 2020
65 $2.3B
Q1 2020 13F
Filed May 15, 2020
61 $1.5B

17 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q2 2023

Largest Q2 2023 13F positions by reported value
# Holding Reported value % of portfolio
1 RETA Reata Pharmaceuticals Inc $145.8M 6.76%
2 APLS Apellis Pharmaceuticals Inc $143.6M 6.66%
3 RVMD Revolution Medicines Inc $125.3M 5.81%
4 TYRA Tyra Biosciences Inc $109.8M 5.09%
5 SWTX Springworks Therapeutics Inc $89.7M 4.16%
6 ONC BeiGene Ltd $89.2M 4.13%
7 AKRO Akero Therapeutics Inc $78.3M 3.63%
8 MRTX Mirati Therapeutics Inc $72.3M 3.35%
9 SRPT Sarepta Therapeutics Inc $68.7M 3.19%
10 CYTK Cytokinetics Inc $68.5M 3.18%
11 IMGN ImmunoGen Inc $55.9M 2.59%
12 KRTX Karuna Therapeutics Inc $54.2M 2.51%
13 IDYA Ideaya Biosciences Inc $51.8M 2.4%
14 SAGE Sage Therapeutics Inc $51.4M 2.39%
15 NUVL Nuvalent Inc $51.0M 2.37%
16 MRUS Merus N V $50.0M 2.32%
17 AMLX Amylyx Pharmaceuticals Inc $45.0M 2.08%
18 LEGN Legend Biotech Corp $41.4M 1.92%
19 ETNB 89Bio Inc $39.8M 1.85%
20 RCUS Arcus Biosciences Inc $32.5M 1.51%

Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings